Biohaven Q4 net loss narrows

Biohaven

02/03/2026 21:21

Overview

Biopharmaceutical company's Q4 net loss narrows to $145.6 mln

Company raised $178.9 mln through common share sales after December 31, 2025

Result Drivers

COST OPTIMIZATION - Strategic cost optimization efforts initiated to focus on three value-driving late-stage clinical programs

Company press release: ID:nPn2gzL6Ya

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$145.56 mln
Q4 Basic EPS
-$1.21
Q4 Operating Expenses
$142.73 mln
Q4 Profit From Operations
-$142.73 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Biohaven Ltd is $16.00, about 38.9% above its February 27 closing price of $11.52

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)